Jim Cramer and Bob Lang go ‘Off the Charts’ with Biotechs – 091713 CELG, GILD, BMRN

“And when you look at 2013’s best performing health care stocks in the S&P 500 the top pure biotech plays are Celgene, Regeneron, and Gilead,” Cramer said.

The phenomenon of window dressing would suggest these stocks should have more room to run. But do they? To either confirm or deny the thesis, Cramer often consults technical analysis. The following technical analysis was provided by Bob Lang, the founder and senior strategist at ExplosiveOptions.net.